Protects cells from premature aging and damage caused by UV radiation
Fatty acid conjugation as used in Semaglutide and Retatrutide promotes reversible albumin binding that shields the peptide from enzymatic degradation and slows renal filtration, extending the half-life from minutes to days
While neither drug is officially approved by the FDA for weight loss, they are frequently used off-label for this purpose
Their evidence base comes from trial programs such as STEP (semaglutide for weight management, published in The New England Journal of Medicine , 2021), SURMOUNT (tirzepatide for weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024)
J Cell Biol (2018) 217(2):45972
Why is glutathione given as a drip rather than a tablet